Summary & Overview
HCPCS J2725: Protirelin Injection, 250 mcg
HCPCS Level II code J2725 identifies a 250 mcg injection of protirelin, used as an injectable diagnostic or therapeutic agent. The code matters nationally because it standardizes billing for protirelin administration across outpatient settings and supports consistent claims processing for a specialized injectable product. Clarity in coding for agents like protirelin affects reimbursement accuracy, provider billing workflows, and payer coverage determinations.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for protirelin injection, typical sites of service where billing occurs, and what to expect in payer coverage patterns. The publication provides benchmarks and coding considerations relevant to claims submission and reimbursement, highlights policy or coverage issues that commonly arise with injectable diagnostic agents, and outlines areas where additional documentation or coding precision influences adjudication. Data not available in the input will be identified explicitly in the relevant sections.
Billing Code Overview
HCPCS Level II code J2725 represents injection, protirelin, per 250 mcg. This code denotes a single dose injectable formulation of protirelin, a diagnostic or therapeutic agent administered by injection.
Service type: Injection / Diagnostic agent administration
Typical site of service: Outpatient clinic, hospital outpatient department, or physician office where injectable diagnostic agents are administered
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult referred to an endocrinology clinic for evaluation of suspected secondary hypothyroidism or central hypothyroidism after abnormal thyroid function tests (low free T4 with low or inappropriately normal TSH) or pituitary pathology. The clinician orders a protirelin (TRH) stimulation test to assess pituitary TSH reserve. The patient arrives to an outpatient infusion or procedure area; informed consent is confirmed, allergy and medication history reviewed, and baseline vital signs and baseline serum TSH and free T4 are obtained. A nurse prepares and administers J2725 (injection, protirelin, per 250 mcg) intravenously as a single bolus. Subsequent blood samples are drawn at specified intervals (commonly 20 and 30 minutes) to measure TSH response. The clinician interprets the stimulated TSH pattern to differentiate primary from secondary or tertiary hypothyroidism or to assess pituitary responsiveness in the setting of known pituitary disease. The patient is observed briefly for adverse reactions (nausea, flushing, local injection reaction) and discharged with results to be discussed at follow-up.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — billed as standard service | Use when no special circumstances apply and full service is rendered |